$238 Million is the total value of GREAT POINT PARTNERS LLC's 25 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 81.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FPRX | Sell | FIVE PRIME THERAPEUTICS INC | $23,641,000 | +25.2% | 569,658 | -53.6% | 9.92% | +32.8% |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $6,743,000 | -21.8% | 355,459 | -21.7% | 2.83% | -17.0% |
| RPTP | Sell | RAPTOR PHARMACEUTICAL CORP | $6,669,000 | -17.4% | 1,282,527 | -3.9% | 2.80% | -12.4% |
| DSCI | Exit | DERMA SCIENCES INC CMN | $0 | – | -101,235 | -100.0% | -0.19% | – |
| DSCO | Exit | DISCOVERY LABORATORIES INC N | $0 | – | -2,530,532 | -100.0% | -0.30% | – |
| THLD | Exit | THRESHOLD PHARMACEUTICALS INCcall | $0 | – | -210,800 | -100.0% | -0.34% | – |
| OSIR | Exit | OSIRIS THERAPEUTICS INC NEW | $0 | – | -75,000 | -100.0% | -0.55% | – |
| AQXP | Exit | AQUINOX PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.56% | – |
| BIOD | Exit | BIODEL INC | $0 | – | -3,316,966 | -100.0% | -0.58% | – |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -1,018,627 | -100.0% | -0.68% | – |
| ALIM | Exit | ALIMERA SCIENCES INC | $0 | – | -1,683,162 | -100.0% | -1.47% | – |
| STML | Exit | STEMLINE THERAPEUTICS INC | $0 | – | -475,200 | -100.0% | -1.66% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -150,000 | -100.0% | -2.25% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCcall | $0 | – | -103,800 | -100.0% | -3.75% | – |
| RLYP | Exit | RELYPSA INC | $0 | – | -769,047 | -100.0% | -5.63% | – |
| DYAX | Exit | DYAX CORP | $0 | – | -750,000 | -100.0% | -5.66% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.